Prothena Corporation PLC (NASDAQ: PRTA) is a clinical-stage biopharmaceutical company that discovers and develops protein dysregulation therapies, primarily targeting neurodegenerative diseases and other conditions driven by misfolded proteins. The company generates revenue through collaboration and licensing agreements rather than product sales, as its drug candidates remain in clinical development as of the 10-K filed 2026-02-27. Prothena is incorporated in Ireland and operates as a development-stage business, meaning it carries no commercial product revenue and funds operations through partnership payments and capital markets. The company's pipeline consists of biologic candidates filed under Biologics License Applications, which, if approved, would qualify for 12-year reference product exclusivity under the Biologics Price Competition and Innovation Act. With no approved products disclosed in the filing excerpts, the business is pre-revenue from product sales and dependent on collaboration income and cash reserves to fund ongoing trials.

Revenue model

Collaboration and licensing agreements. No commercial product revenue disclosed in the FY2025 10-K (filed 2026-02-27). Revenue is milestone- and royalty-based from partnership arrangements.

Products and services

Clinical-stage biologic drug candidates targeting protein dysregulation and neurodegenerative diseases. Candidates are filed as biologics under BLA pathway and would carry 12-year reference product exclusivity if approved.

Customers and end markets

Pharmaceutical and biotechnology collaboration partners. End markets are neurodegenerative and protein misfolding diseases. No commercial customers disclosed in the filing excerpts.

Value-chain role

Drug discovery and clinical development. Pre-commercial stage; licenses or co-develops assets with larger pharmaceutical partners.

Geographic exposure

Incorporated in Ireland. U.S. FDA regulatory framework governs drug approval pathway. No specific revenue by geography disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-02-27

Industry: Pharmaceutical Preparations Peers: Alkermes Plc Amarin Corporation PLC Horizon Therapeutics Public Ltd Co